Zacks Investment Research on MSN20h
Mirum's Heavy Dependence on Livmarli for Revenues Remains a WoeMirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback